Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

BACKGROUND: We assessed safety, immunogenicity and clinical activity of recombinant MAGE-A3 antigen combined with AS15 immunostimulant (MAGE-A3 immunotherapeutic) in association with dacarbazine in patients with metastatic melanoma. METHODS: In this open-label, phase I/II, uncontrolled multicentre t...

Descripción completa

Detalles Bibliográficos
Autores principales: Grob, Jean-Jacques, Mortier, Laurent, D’Hondt, Lionel, Grange, Florent, Baurain, Jean Francois, Dréno, Brigitte, Lebbe, Céleste, Robert, Caroline, Dompmartin, Anne, Neyns, Bart, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687540/
https://www.ncbi.nlm.nih.gov/pubmed/29177094
http://dx.doi.org/10.1136/esmoopen-2017-000203

Ejemplares similares

Ejemplares similares